Endo International Stock Price, News & Analysis (NASDAQ:ENDP)

$6.56 -0.13 (-1.94 %)
(As of 02/22/2018 04:00 PM ET)
Previous Close$6.56
Today's Range$6.51 - $6.85
52-Week Range$5.77 - $14.45
Volume3.48 million shs
Average Volume5.68 million shs
Market Capitalization$1.49 billion
P/E Ratio-0.34
Dividend YieldN/A
Beta0.29

About Endo International (NASDAQ:ENDP)

Endo International logoEndo International PLC, formerly Endo Health Solutions Inc. is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel. The Company operates in three segments: Endo Pharmaceuticals, Qualitest and AMS. In June 2014, the Company's subsidiary, Endo Pharmaceuticals sold its pharmaceutical drug discovery platform to AsanaBioSciences, LLC. In June 2014, Asana BioSciences, LLC, an independent member of Amneal Alliance of Companies, acquired early-stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International plc. In June 2014, Trendlines Group acquired intellectual property developed within the framework of an R&D agreement with the Company. In July 2014, it acquired Grupo Farmaceutico Somar.

Receive ENDP News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Other
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ENDP
CUSIP29264F20
Phone011-353-1268-2000

Debt

Debt-to-Equity Ratio10.78%
Current Ratio1.08%
Quick Ratio0.86%

Price-To-Earnings

Trailing P/E Ratio-0.340248962655602
Forward P/E Ratio1.79
P/E Growth2.37

Sales & Book Value

Annual Sales$4.01 billion
Price / Sales0.37
Cash Flow$8.99 per share
Price / Cash0.73
Book Value$12.12 per share
Price / Book0.54

Profitability

Trailing EPS($19.28)
Net Income$-3,347,060,000.00
Net Margins-126.97%
Return on Equity66.98%
Return on Assets8.38%

Miscellaneous

Employees4,894
Outstanding Shares223,310,000

Endo International (NASDAQ:ENDP) Frequently Asked Questions

What is Endo International's stock symbol?

Endo International trades on the NASDAQ under the ticker symbol "ENDP."

How were Endo International's earnings last quarter?

Endo International plc - (NASDAQ:ENDP) announced its earnings results on Thursday, November, 9th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.85 by $0.06. The firm earned $786.90 million during the quarter, compared to analyst estimates of $794.93 million. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. Endo International's revenue was down 11.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.01 EPS. View Endo International's Earnings History.

When will Endo International make its next earnings announcement?

Endo International is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Endo International.

Where is Endo International's stock going? Where will Endo International's stock price be in 2018?

18 analysts have issued 1 year price objectives for Endo International's shares. Their forecasts range from $7.00 to $20.00. On average, they expect Endo International's stock price to reach $10.47 in the next year. View Analyst Ratings for Endo International.

What are Wall Street analysts saying about Endo International stock?

Here are some recent quotes from research analysts about Endo International stock:

  • 1. According to Zacks Investment Research, "While Endo's Sterile Injectables and Branded Specialty products business units continue to perform well, the decline in generics industry persist thereby impacting the company's top-line. The branded pharmaceuticals business contiinues to be impacted by continued generic competition for established products, product divestitures and ceasing shipments of Opana ER. The business is expected to decline further as the year progresses. Endo withdrew opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA’s request in June. The drug represented 4% of total 2016 revenues. The company divested its non-core assets such as Belbuca and restructured its pain franchise to focus particularly on specialty branded business. Shares have underperformed the indutsry in the past one year." (1/15/2018)
  • 2. Mizuho analysts commented, "We Lower PT to $12 from $14; Buy on Valuation Rating Buy Previous Rating No Change Price (1/02) $8.10 Price Target $12.00 Previous Price Target $14.00 Summary We reiterate our Buy rating but lower our PT to $12 from $14. We think 2018 guidance may prove disappointing, but we continue to view the stock as undervalued." (1/3/2018)
  • 3. JMP Securities analysts commented, "The FDA panel voted 8 yes, 18 no, and 1 abstain on whether Opana ER's benefits outweigh the risk. The FDA was concerned that the new Opana ER formulation just shifts the abuse route from nasal to injections. We do not view Opana ER as a growth driver and it is only 4% of our 2017 revenue estimate while declining 13% y/y. Our $20 price target includes an equal blend of PEG ratio and EV/EBITDA analysis of 1.3x and 8.5x, respectively, on our 2017 estimates." (3/15/2017)

Are investors shorting Endo International?

Endo International saw a increase in short interest in January. As of January 31st, there was short interest totalling 22,990,959 shares, an increase of 6.3% from the January 12th total of 21,627,873 shares. Based on an average daily volume of 5,804,781 shares, the short-interest ratio is presently 4.0 days. Currently, 11.5% of the company's shares are short sold.

Who are some of Endo International's key competitors?

Who owns Endo International stock?

Endo International's stock is owned by a number of of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (0.98%), First Quadrant L P CA (0.90%), Geode Capital Management LLC (0.79%), Hexavest Inc. (0.51%), River & Mercantile Asset Management LLP (0.21%) and TIAA CREF Investment Management LLC (0.17%). Company insiders that own Endo International stock include Arthur J Higgins, Blaise Coleman, Matthew Joseph Maletta, Nancy J Hutson, Paul Campanelli, Roger H Kimmel, Silva Rajiv De, Terrance J Coughlin and William Spengler. View Institutional Ownership Trends for Endo International.

Who sold Endo International stock? Who is selling Endo International stock?

Endo International's stock was sold by a variety of institutional investors in the last quarter, including Teachers Advisors LLC, TIAA CREF Investment Management LLC, Hexavest Inc., Bank of New York Mellon Corp, Geode Capital Management LLC, First Quadrant L P CA, Gabelli Funds LLC and Crossmark Global Holdings Inc.. View Insider Buying and Selling for Endo International.

Who bought Endo International stock? Who is buying Endo International stock?

Endo International's stock was purchased by a variety of institutional investors in the last quarter, including Quantitative Investment Management LLC, River & Mercantile Asset Management LLP, Amundi Pioneer Asset Management Inc., Alps Advisors Inc., Hudson Bay Capital Management LP, New Mexico Educational Retirement Board, Schroder Investment Management Group and Systematic Financial Management LP. Company insiders that have bought Endo International stock in the last two years include Arthur J Higgins, Blaise Coleman, Matthew Joseph Maletta, Paul Campanelli, Roger H Kimmel, Silva Rajiv De, Terrance J Coughlin and William Spengler. View Insider Buying and Selling for Endo International.

How do I buy Endo International stock?

Shares of Endo International can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endo International's stock price today?

One share of Endo International stock can currently be purchased for approximately $6.56.

How big of a company is Endo International?

Endo International has a market capitalization of $1.49 billion and generates $4.01 billion in revenue each year. The company earns $-3,347,060,000.00 in net income (profit) each year or ($19.28) on an earnings per share basis. Endo International employs 4,894 workers across the globe.

How can I contact Endo International?

Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]


MarketBeat Community Rating for Endo International (ENDP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  649 (Vote Outperform)
Underperform Votes:  599 (Vote Underperform)
Total Votes:  1,248
MarketBeat's community ratings are surveys of what our community members think about Endo International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Endo International (NASDAQ:ENDP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.222.212.152.25
Ratings Breakdown: 1 Sell Rating(s)
12 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
13 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
15 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
15 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.47$10.97$11.81$14.94
Price Target Upside: 54.63% upside35.92% upside70.45% upside96.12% upside

Endo International (NASDAQ:ENDP) Consensus Price Target History

Price Target History for Endo International (NASDAQ:ENDP)

Endo International (NASDAQ:ENDP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/21/2018Canaccord GenuitySet Price TargetHold -> Hold$8.00 -> $7.00MediumView Rating Details
2/14/2018B. RileyInitiated CoverageBuy -> Buy$10.00HighView Rating Details
1/11/2018Cantor FitzgeraldSet Price TargetHold$7.00LowView Rating Details
1/3/2018MizuhoReiterated RatingBuy -> Buy$14.00 -> $12.00HighView Rating Details
1/2/2018Leerink SwannInitiated CoverageOutperform -> Outperform$12.00HighView Rating Details
12/12/2017GuggenheimInitiated CoverageNeutral -> Neutral$8.50LowView Rating Details
11/10/2017Piper Jaffray CompaniesReiterated RatingHold$7.00N/AView Rating Details
11/10/2017BMO Capital MarketsLower Price TargetMarket Perform$11.00 -> $10.00N/AView Rating Details
11/10/2017CitigroupLower Price TargetNeutral$9.00 -> $7.00N/AView Rating Details
11/10/2017Royal Bank of CanadaLower Price TargetSector Perform -> Sector Perform$9.00 -> $8.00N/AView Rating Details
9/28/2017Goldman Sachs GroupInitiated CoverageSell -> Sell$7.00HighView Rating Details
8/10/2017Morgan StanleyLower Price TargetEqual Weight$12.00 -> $8.00LowView Rating Details
8/10/2017CowenReiterated RatingHold$16.00HighView Rating Details
8/9/2017Deutsche BankSet Price TargetBuy$15.00 -> $13.00LowView Rating Details
8/8/2017OppenheimerReiterated RatingHoldHighView Rating Details
6/14/2017William BlairReiterated RatingMarket PerformLowView Rating Details
6/9/2017Stifel NicolausDowngradeBuy -> Hold$22.00 -> $15.00HighView Rating Details
3/15/2017JMP SecuritiesReiterated RatingOutperform$20.00HighView Rating Details
2/6/2017BarclaysLower Price TargetEqual Weight$22.00 -> $15.00N/AView Rating Details
1/31/2017Susquehanna BancsharesUpgradeNeutral -> PositiveN/AView Rating Details
1/20/2017JPMorgan Chase & Co.DowngradeOverweight -> Neutral$20.00N/AView Rating Details
9/29/2016Northland SecuritiesUpgradeMarket Perform -> Outperform$27.00N/AView Rating Details
4/2/2016NomuraReiterated RatingBuyN/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Endo International (NASDAQ:ENDP) Earnings History and Estimates Chart

Earnings by Quarter for Endo International (NASDAQ:ENDP)

Endo International (NASDAQ ENDP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018$0.61N/AView Earnings Details
11/9/2017Q3$0.85$0.91$794.93 million$786.90 millionViewN/AView Earnings Details
8/8/20176/30/2017$0.74$0.93$832.66 million$875.73 millionViewListenView Earnings Details
5/9/2017Q1 17$1.10$1.23$1.02 billion$1.04 billionViewListenView Earnings Details
2/28/2017Q416$1.63$1.77$1.17 billion$1.24 billionViewListenView Earnings Details
11/8/2016Q316$0.81$1.01$862.47 million$894.30 millionViewListenView Earnings Details
8/8/2016Q216$0.74$0.86$873.50 million$921.00 millionViewListenView Earnings Details
5/5/2016Q116$1.04$1.08$960.96 million$963.54 millionViewListenView Earnings Details
2/29/2016Q415$1.27$1.36$1.07 billion$1.07 billionViewListenView Earnings Details
11/5/2015Q315$1.00$1.02$736.16 million$746.00 millionViewListenView Earnings Details
8/10/2015Q215$1.02$1.08$727.45 million$735.00 millionViewListenView Earnings Details
5/11/2015Q115$1.07$1.17$714.42 million$714.00 millionViewListenView Earnings Details
3/2/2015Q414$1.13$1.16$780.44 million$800.00 millionViewListenView Earnings Details
11/5/2014Q314$0.99$1.15$721.11 million$764.00 millionViewListenView Earnings Details
7/31/2014Q214$0.90$1.06$644.60 million$719.00 millionViewListenView Earnings Details
5/1/2014Q114$0.84$0.92$608.86 million$595.00 millionViewListenView Earnings Details
2/28/2014Q413$0.93$0.96$620.90 million$584.95 millionViewListenView Earnings Details
11/7/2013Q313$1.11$1.34$695.63 million$715.00 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.15$1.42$721.01 million$766.51 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.08$1.09$737.79 million$709.00 millionViewListenView Earnings Details
2/28/2013Q4 2012$1.54$1.62$807.98 million$801.06 millionViewListenView Earnings Details
11/5/2012Q312$1.26$1.28$788.53 million$750.50 millionViewN/AView Earnings Details
8/7/2012$1.19$1.27ViewN/AView Earnings Details
5/1/2012$0.86$0.87ViewN/AView Earnings Details
2/24/2012$1.32$1.40ViewN/AView Earnings Details
10/27/2011$1.28$1.25ViewN/AView Earnings Details
8/9/2011$1.06$1.05ViewN/AView Earnings Details
4/28/2011$1.00$1.00ViewN/AView Earnings Details
2/28/2011$0.97$1.06ViewN/AView Earnings Details
11/1/2010Q3 2010$0.85$0.87ViewN/AView Earnings Details
7/30/2010Q2 2010$0.80$0.81ViewN/AView Earnings Details
4/30/2010Q1 2010$0.75$0.74ViewN/AView Earnings Details
2/22/2010Q4 2009$0.68$0.81ViewN/AView Earnings Details
10/29/2009Q3 2009$0.64$0.63ViewN/AView Earnings Details
7/30/2009Q2 2009$0.67$0.73ViewN/AView Earnings Details
4/29/2009Q1 2009$0.60$0.67ViewN/AView Earnings Details
2/27/2009Q4 2008$0.59$0.66ViewN/AView Earnings Details
10/30/2008Q3 2008$0.52$0.61ViewN/AView Earnings Details
7/31/2008Q2 2008$0.49$0.57ViewN/AView Earnings Details
4/30/2008Q1 2008$0.47$0.51ViewN/AView Earnings Details
2/22/2008Q4 2007$0.44$0.50ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Endo International (NASDAQ:ENDP) Earnings Estimates

2018 EPS Consensus Estimate: $2.84
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.60$0.70$0.65
Q2 20183$0.67$0.76$0.70
Q3 20183$0.67$0.73$0.71
Q4 20183$0.71$0.83$0.78
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Endo International (NASDAQ:ENDP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Endo International (NASDAQ ENDP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.50%
Institutional Ownership Percentage: 92.54%
Insider Trades by Quarter for Endo International (NASDAQ:ENDP)
Insider Trades by Quarter for Endo International (NASDAQ:ENDP)

Endo International (NASDAQ ENDP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/15/2017Blaise ColemanCFOBuy6,500$7.89$51,285.0013,729View SEC Filing  
8/15/2017Matthew Joseph MalettaEVPBuy3,000$8.02$24,060.006,984View SEC Filing  
8/14/2017Paul CampanelliCEOBuy6,500$7.71$50,115.00213,620View SEC Filing  
8/10/2017Terrance J CoughlinCOOBuy20,000$7.70$154,000.00181,369View SEC Filing  
3/16/2017Paul CampanelliCEOBuy2,300$10.72$24,656.00207,120View SEC Filing  
3/9/2017Nancy J. HutsonDirectorSell5,325$10.82$57,616.50View SEC Filing  
11/15/2016Roger H. KimmelDirectorSell14,000$17.38$243,320.00View SEC Filing  
5/11/2016Arthur J HigginsDirectorBuy5,000$13.80$69,000.0050,623View SEC Filing  
5/10/2016Arthur J HigginsDirectorBuy11,000$15.42$169,620.0045,623View SEC Filing  
5/10/2016Paul CampanelliInsiderBuy13,000$15.53$201,890.00201,069View SEC Filing  
3/17/2016William SpenglerDirectorBuy1,000$29.20$29,200.0048,835View SEC Filing  
3/16/2016William SpenglerDirectorBuy1,000$35.24$35,240.0047,835View SEC Filing  
3/14/2016Roger H KimmelDirectorBuy1,125$41.94$47,182.5072,237View SEC Filing  
3/7/2016Matthew Joseph MalettaVPBuy500$44.48$22,240.001,000View SEC Filing  
3/7/2016Silva Rajiv DeCEOBuy2,250$44.50$100,125.00250,705View SEC Filing  
3/1/2016Nancy J. HutsonDirectorSell3,413$42.19$143,994.4739,990View SEC Filing  
11/12/2015Shane CookeDirectorBuy4,000$57.13$228,520.0010,179View SEC Filing  
11/11/2015Michael HyattDirectorSell8,000$55.48$443,840.00251,599View SEC Filing  
11/11/2015Paul CampanelliinsiderBuy2,100$55.69$116,949.0015,367View SEC Filing  
11/11/2015Silva Rajiv DeCEOBuy9,006$55.52$500,013.1213,697View SEC Filing  
11/11/2015Suketu UpadhyayCFOBuy4,450$56.37$250,846.5017,740View SEC Filing  
11/11/2015Susan HallEVPBuy1,000$55.35$55,350.007,515View SEC Filing  
6/16/2015Arthur J HigginsDirectorBuy2,500$81.10$202,750.00View SEC Filing  
4/8/2015Caroline B ManogueVPSell105,562$91.90$9,701,147.80View SEC Filing  
11/14/2014Suketu UpadhyayCFOBuy3,700$66.94$247,678.00View SEC Filing  
8/5/2014Arthur J HigginsDirectorBuy3,500$65.65$229,775.00View SEC Filing  
6/9/2014John DeluccaDirectorSell6,764$68.83$465,566.12View SEC Filing  
5/29/2014Caroline B ManogueVPSell175,033$72.02$12,605,876.66View SEC Filing  
5/1/2014John DeluccaDirectorSell8,094$66.31$536,713.1421,596View SEC Filing  
4/1/2014John DeluccaDirectorSell10,384$68.46$710,888.6421,596View SEC Filing  
3/10/2014Arthur HigginsDirectorBuy5,000$73.00$365,000.005,000View SEC Filing  
3/10/2014Ivan GergelEVPSell75,637$72.47$5,481,413.3927,649View SEC Filing  
8/26/2013Caroline ManogueVPSell145,592$39.40$5,736,324.8046,422View SEC Filing  
8/8/2013Roger KimmelDirectorBuy5,478$36.50$199,947.0051,914View SEC Filing  
4/9/2013Caroline B ManogueVPSell35,000$35.00$1,225,000.00View SEC Filing  
11/12/2012David HolveckCEOBuy7,425$26.84$199,287.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Endo International (NASDAQ ENDP) News Headlines

Source:
DateHeadline
 Analysts Expect Endo International plc - (ENDP) Will Announce Earnings of $0.62 Per Share Analysts Expect Endo International plc - (ENDP) Will Announce Earnings of $0.62 Per Share
www.americanbankingnews.com - February 22 at 2:12 PM
Endo International (ENDP) PT Set at $7.00 by Canaccord GenuityEndo International (ENDP) PT Set at $7.00 by Canaccord Genuity
www.americanbankingnews.com - February 21 at 4:22 PM
Technical Perspectives on Drug Makers Stocks -- Depomed, DURECT, Endo, and Ionis Pharma - PR Newswire (press release)Technical Perspectives on Drug Makers Stocks -- Depomed, DURECT, Endo, and Ionis Pharma - PR Newswire (press release)
www.prnewswire.com - February 21 at 8:15 AM
Endo International (ENDP) Set to Announce Earnings on TuesdayEndo International (ENDP) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - February 20 at 3:28 AM
B. Riley Comments on Endo International plc -s FY2017 Earnings (ENDP)B. Riley Comments on Endo International plc -'s FY2017 Earnings (ENDP)
www.americanbankingnews.com - February 16 at 6:04 AM
Endo International (ENDP) Now Covered by B. RileyEndo International (ENDP) Now Covered by B. Riley
www.americanbankingnews.com - February 14 at 7:12 AM
OxyContin maker stops promoting opioids, cuts sales staffOxyContin maker stops promoting opioids, cuts sales staff
finance.yahoo.com - February 11 at 9:13 AM
Endo International plc - (ENDP) Short Interest UpdateEndo International plc - (ENDP) Short Interest Update
www.americanbankingnews.com - February 9 at 4:58 PM
Endo International (ENDP) to Commence Two Pivotal Phase 3 Clinical Trials Of Collagenase Clostridium Histolyticum ... - StreetInsider.comEndo International (ENDP) to Commence Two Pivotal Phase 3 Clinical Trials Of Collagenase Clostridium Histolyticum ... - StreetInsider.com
www.streetinsider.com - February 8 at 3:38 PM
Q3 2018 EPS Estimates for Endo International plc - Boosted by Analyst (ENDP)Q3 2018 EPS Estimates for Endo International plc - Boosted by Analyst (ENDP)
www.americanbankingnews.com - February 7 at 9:55 AM
$765.33 Million in Sales Expected for Endo International plc - (ENDP) This Quarter$765.33 Million in Sales Expected for Endo International plc - (ENDP) This Quarter
www.americanbankingnews.com - February 7 at 4:36 AM
Endo begins late-stage testing of potential cellulite treatmentEndo begins late-stage testing of potential cellulite treatment
finance.yahoo.com - February 6 at 3:38 PM
Endo International plc - (ENDP) to Post Q1 2018 Earnings of $0.70 Per Share, Leerink Swann ForecastsEndo International plc - (ENDP) to Post Q1 2018 Earnings of $0.70 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - February 6 at 8:56 AM
Endo Announces Initiation Of Two Pivotal Phase 3 Clinical Trials Of Collagenase Clostridium Histolyticum For The Treatment Of CelluliteEndo Announces Initiation Of Two Pivotal Phase 3 Clinical Trials Of Collagenase Clostridium Histolyticum For The Treatment Of Cellulite
finance.yahoo.com - February 6 at 8:48 AM
$0.63 Earnings Per Share Expected for Endo International plc - (ENDP) This Quarter$0.63 Earnings Per Share Expected for Endo International plc - (ENDP) This Quarter
www.americanbankingnews.com - February 5 at 1:26 PM
Endo International (ENDP) Stock Rating Lowered by BidaskClubEndo International (ENDP) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - January 31 at 11:58 PM
Endo International plc - (ENDP) Receives Consensus Recommendation of "Hold" from BrokeragesEndo International plc - (ENDP) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 30 at 3:34 PM
Endo to Announce Fourth-Quarter 2017 Financial ResultsEndo to Announce Fourth-Quarter 2017 Financial Results
finance.yahoo.com - January 29 at 8:58 AM
Endo International plc - (ENDP) to Post Q4 2017 Earnings of $0.58 Per Share, Leerink Swann ForecastsEndo International plc - (ENDP) to Post Q4 2017 Earnings of $0.58 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - January 29 at 1:26 AM
Everything That Could Go Wrong for This Drugmaker DidEverything That Could Go Wrong for This Drugmaker Did
finance.yahoo.com - January 26 at 8:37 AM
Oppenheimer Comments on Endo International plc -s Q4 2017 Earnings (ENDP)Oppenheimer Comments on Endo International plc -'s Q4 2017 Earnings (ENDP)
www.americanbankingnews.com - January 24 at 8:16 AM
[$$] New York City Sues Companies Over Opioid Abuse[$$] New York City Sues Companies Over Opioid Abuse
finance.yahoo.com - January 23 at 5:31 PM
FY2017 Earnings Forecast for Endo International plc - (ENDP) Issued By OppenheimerFY2017 Earnings Forecast for Endo International plc - (ENDP) Issued By Oppenheimer
www.americanbankingnews.com - January 23 at 8:50 AM
$764.99 Million in Sales Expected for Endo International plc - (ENDP) This Quarter$764.99 Million in Sales Expected for Endo International plc - (ENDP) This Quarter
www.americanbankingnews.com - January 21 at 5:48 AM
Delaware sues opioid manufacturers, distributors over epidemicDelaware sues opioid manufacturers, distributors over epidemic
finance.yahoo.com - January 19 at 5:47 PM
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endo International plc (ENDP) & Lead Plaintiff Deadline - January 16, 2018FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endo International plc (ENDP) & Lead Plaintiff Deadline - January 16, 2018
finance.yahoo.com - January 16 at 5:13 PM
Endo (ENDP) Loses 35% in a Year: Can It Turn Around in 2018?Endo (ENDP) Loses 35% in a Year: Can It Turn Around in 2018?
www.zacks.com - January 16 at 9:38 AM
FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endo International plc (ENDP) & Lead Plaintiff Deadline - January 16, 2018FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endo International plc (ENDP) & Lead Plaintiff Deadline - January 16, 2018
finance.yahoo.com - January 15 at 5:15 PM
Endo International (ENDP) Stock Rating Lowered by Zacks Investment ResearchEndo International (ENDP) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 15 at 4:28 PM
Endo International (ENDP) Rating Lowered to Sell at BidaskClubEndo International (ENDP) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - January 15 at 12:44 AM
Endo International plc - (ENDP) Sees Large Decrease in Short InterestEndo International plc - (ENDP) Sees Large Decrease in Short Interest
www.americanbankingnews.com - January 13 at 2:04 AM
Endo (ENDP) Comments on U.S Attorneys Office Grand Jury Subpoena Relating to Products Containing OxymorphoneEndo (ENDP) Comments on U.S Attorney's Office Grand Jury Subpoena Relating to Products Containing Oxymorphone
www.streetinsider.com - January 11 at 5:23 PM
Interesting ENDP Put And Call Options For March 2ndInteresting ENDP Put And Call Options For March 2nd
www.nasdaq.com - January 11 at 5:23 PM
[$$] Government Subpoenas Endo Pharmaceuticals for Information on Opioid Products[$$] Government Subpoenas Endo Pharmaceuticals for Information on Opioid Products
finance.yahoo.com - January 11 at 5:23 PM
Endo Comments on United States Attorneys Office Grand Jury Subpoena Relating to Products Containing OxymorphoneEndo Comments on United States Attorney's Office Grand Jury Subpoena Relating to Products Containing Oxymorphone
finance.yahoo.com - January 11 at 9:53 AM
Endo subpoenaed for information on opioid painkillersEndo subpoenaed for information on opioid painkillers
finance.yahoo.com - January 11 at 9:53 AM
Endo gets subpoena for drugs containing opioid painkillerEndo gets subpoena for drugs containing opioid painkiller
finance.yahoo.com - January 11 at 9:53 AM
Endo International gets grand jury subpoena from Florida over oxymorphone, stock slides almost 6%Endo International gets grand jury subpoena from Florida over oxymorphone, stock slides almost 6%
finance.yahoo.com - January 11 at 9:53 AM
Endo receives grand jury subpoena for opioid-related documentsEndo receives grand jury subpoena for opioid-related documents
finance.yahoo.com - January 11 at 9:53 AM
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endo International plc (ENDP) & Lead Plaintiff Deadline - January 16, 2018DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endo International plc (ENDP) & Lead Plaintiff Deadline - January 16, 2018
finance.yahoo.com - January 10 at 5:14 PM
Traders Buy High Volume of Endo International Put Options (ENDP)Traders Buy High Volume of Endo International Put Options (ENDP)
www.americanbankingnews.com - January 6 at 2:08 AM
Endo International plc - (ENDP) Given Average Rating of "Hold" by AnalystsEndo International plc - (ENDP) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - January 5 at 3:28 PM
FY2017 Earnings Estimate for Endo International plc - Issued By Leerink Swann (ENDP)FY2017 Earnings Estimate for Endo International plc - Issued By Leerink Swann (ENDP)
www.americanbankingnews.com - January 5 at 8:38 AM
Endo International plc - (ENDP) to Post Q3 2018 Earnings of $0.76 Per Share, Leerink Swann ForecastsEndo International plc - (ENDP) to Post Q3 2018 Earnings of $0.76 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - January 4 at 1:42 PM
Endo International plc (ENDP)Endo International plc (ENDP)
finance.yahoo.com - January 4 at 9:32 AM
Glancy Prongay & Murray Announces Filing of a Securities Class Action on Behalf of Endo International, PLC Investors and Encourages Investors to Contact the FirmGlancy Prongay & Murray Announces Filing of a Securities Class Action on Behalf of Endo International, PLC Investors and Encourages Investors to Contact the Firm
finance.yahoo.com - January 4 at 9:32 AM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endo International plc (ENDP) & Lead Plaintiff Deadline - January 16, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endo International plc (ENDP) & Lead Plaintiff Deadline - January 16, 2018
finance.yahoo.com - January 3 at 5:19 PM
Endo International Plc :ENDP-US: Earnings Analysis: Q3, 2017 By the Numbers : January 3, 2018Endo International Plc :ENDP-US: Earnings Analysis: Q3, 2017 By the Numbers : January 3, 2018
finance.yahoo.com - January 3 at 8:44 AM
$0.62 Earnings Per Share Expected for Endo International plc - (ENDP) This Quarter$0.62 Earnings Per Share Expected for Endo International plc - (ENDP) This Quarter
www.americanbankingnews.com - January 2 at 7:12 PM
Endo International (ENDP) Receives New Coverage from Analysts at Leerink SwannEndo International (ENDP) Receives New Coverage from Analysts at Leerink Swann
www.americanbankingnews.com - January 2 at 5:18 PM

SEC Filings

Endo International (NASDAQ:ENDP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Endo International (NASDAQ:ENDP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Endo International (NASDAQ ENDP) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.